Impact of tolvaptan add-on treatment on patients with heart failure requiring long-term congestion management: A retrospective cohort study using a medical claim database in Japan
CONCLUSIONS: Tolvaptan did not significantly affect time to HF rehospitalization. However, further worsening of the condition leading to death may be delayed, and time to in-hospital death may be prolonged in patients treated with tolvaptan, indicating its usefulness for long-term congestion management.PMID:36587792 | DOI:10.1016/j.jjcc.2022.12.006
Source: Journal of Cardiology - Category: Cardiology Authors: Koichiro Kinugawa Miyuki Matsukawa Yumiko Nakamura Miki Aihara Hiromi Sano Source Type: research
More News: Cardiology | Databases & Libraries | Furosemide | Heart | Heart Failure | Japan Health | Sodium | Study